Overview

Multidisciplinary Study of Novel NMDA Modulation for Neurodegenerative Disorder

Status:
Recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
Alzheimer's disease (AD) and Parkinson's disease (PD) are currently the leading neurodegenerative disorders. Considering the fact that aged population is rapidly growing, it has become a critical issue to find more effective medications for these two disorders. The aim of this project is to examine the effectiveness and safety of DAAOI-P treatment for PD with dementia.
Phase:
Phase 2
Details
Lead Sponsor:
China Medical University Hospital
Collaborator:
Ministry of Science and Technology, Taiwan